<DOC>
	<DOCNO>NCT02257372</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel-group study evaluate efficacy safety addition UMEC ( 62.5 microgram [ mcg ] ) administer once-daily via dry powder inhaler ( DPI ) Inhaled corticosteroid/ Long-acting beta2-agonist ( ICS/LABA ) twice-daily compare placebo via DPI add ICS/LABA therapy treatment period 12 week subject COPD . This study design investigate addition UMEC ICS/LABA combination approve dos frequency treatment COPD include SERETIDE™ 500/50 mcg twice daily , Fluticasone Propionate/Salmeterol Combination ( FSC ) 500/50 twice daily generic product AIRFLUSAL FORSPIRO inhaler 500/50 mcg twice daily ROLENIUM ELPENHALER inhaler 500/50 mcg twice daily SYMBICORT TURBUHALER inhaler dose 200/6 mcg twice daily 400/12 mcg twice daily , 12 week subject COPD . Albuterol/salbutamol metered-dose-inhaler ( MDI ) nebules issue throughout study use as-needed ( prn ) . Subjects meet eligibility criterion randomly assign one follow blind study treatment regimens equal proportion ( 1:1 ) : UMEC 62.5 mcg once-daily Placebo once-daily . Approximately 230 subject ( 115 subject per treatment ) randomize order complete least 206 evaluable subject . The total duration study approximately 14 week subject . UMEC Long-acting Muscarinic Antagonist ( LAMA ) currently development monotherapy , combination product LABA , vilanterol ( VI ) , treatment COPD , combination product ICS , fluticasone furoate ( FF ) , treatment asthma . The UMEC/VI combination 62.5/25 .mcg once-daily approve United States ( U.S. ) Canada COPD trade name ANORO™ ELLIPTA™ regulatory review country . SERETIDE , ANORO , ELLIPTA trade mark GlaxoSmithKline Group Companies . Other company product name mention herein may property respective owner .</brief_summary>
	<brief_title>A Study Evaluate Effect Umeclidinium ( UMEC ) Combination Therapy Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Type subject : Outpatient . Informed Consent : A sign date write informed consent prior study participation . Age : Subjects 40 year age old Visit 1 . Gender : Male female subject eligible participate study . A female eligible enter participate study : Nonchild bear potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy . OR Child bear potential , negative pregnancy test screening , agree one follow acceptable contraceptive method use consistently correctly ( i.e. , accordance approve product label instruction physician duration study screen followup contact ) : Abstinence ; Oral Contraceptive , either combined progestogen alone ; Injectable progestogen ; Implants levonorgestrel ; Estrogenic vaginal ring ; Percutaneous contraceptive patch ; Intrauterine device ( IUD ) intrauterine system ( IUS ) meet Standard Operating Procedure ( SOP ) effectiveness criterion state product label ; Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject . For definition , `` document '' refers outcome investigator's/designee 's medical examination subject review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society Smoking History : Current former cigarette smoker history cigarette smoke &gt; =10 packyears [ number pack year = ( number cigarette per day / 20 ) x number year smoke ( e.g. , 20 cigarette per day 10 year , 10 cigarette per day 20 year ) ] . Former smoker define stop smoke least 6 month prior Visit 1 . Pipe and/or cigar use use calculate pack year history . Severity Disease : A pre postalbuterol/salbutamol Forced Expiratory Volume One Second /Forced Vital Capacity ( FEV1/FVC ) ratio &lt; 0.70 postalbuterol/salbutamol FEV1 &lt; =70 % predict normal value Visit 1 ( Screening ) calculate use reference value provide Quanjer . Current clinically prescribe medication : The subject must dose frequency one follow ICS/LABA combination approve COPD least 30 day prior screen : FSC dose 500/50 mcg twicedaily ( i.e . SERETIDE DISKUS™ inhaler approve generic product AIRFLUSAL FORSPIRO inhaler 500/50 mcg twice daily ROLENIUM ELPENHALER inhaler 500/50 mcg twice daily ) ; The combination budesonide/formoterol ( i.e. , SYMBICORT TURBUHALER inhaler ) dose 200/6 mcg twicedaily 400/12 mcg twicedaily . Dyspnea : A score &gt; =2 Modified Medical Research Council ( mMRC ) Dyspnea Scale Visit 1 . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known alpha1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , opinion investigator , significant respiratory condition addition COPD exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Other Diseases/Abnormalities : The subject consider unlikely survive duration study period rapidly progress disease immediately lifethreatening illness e.g . cancer . Contraindications : Any history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , sympathomimetic , corticosteroid ( intranasal , inhaled systemic ) lactose/milk protein magnesium stearate . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lower respiratory tract infection : Subjects low respiratory tract infection require use antibiotic within 6 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Visit 1 . Unstable life threaten cardiac disease : UMEC use caution subject severe cardiovascular disease . In opinion investigator , use consider benefit likely outweigh risk condition : Myocardial infarction unstable angina last 6 month ; Unstable life threaten cardiac arrhythmia require intervention last 3 month ; New York Heart Association ( NYHA ) Class IV heart failure 12Lead Electrocardiogram ( ECG ) : Investigators provide ECG review conduct centralized independent cardiologist assist evaluation subject eligibility . The Principle Investigator determine clinical significance abnormal ECG find relation subject 's medical history exclude subject would undue risk participate trial . Subjects follow abnormality exclude participation study : Atrial fibrillation rapid ventricular rate &gt; 120 beat per minute ( bpm ) ; Sustained nonsustained ventricular tachycardia ; Second degree heart block Mobitz type II third degree heart block ( unless pacemaker defibrillator insert ) Antimuscarinic effect : Subjects medical condition narrowangle glaucoma , prostatic hypertrophy , bladder neck obstruction include , opinion study physician , benefit outweighs risk . Interactions : Concomitant administration betablockers strong Cytochrome P450 3A4 ( CYP3A4 ) inhibitor permit , Investigator 's opinion , likely benefit outweigh potential risk . Severe Hepatic Impairment : Patients severe hepatic impairment ( ChildPugh class C ) exclude unless , opinion investigator , benefit likely outweigh risk . Medication Prior Spirometry : Unable withhold albuterol/salbutamol 4 hour period require prior spirometry test study visit . Medications Prior Screening : Use follow medication accord follow defined time interval prior Visit 1 : Depot corticosteroid ( 12 week ) , Systemic , oral parenteral corticosteroid ( 6 week ) ; Antibiotics ( low respiratory tract infection ) ( 6 week ) ; CYP3A4 strong inhibitor ( 6 week ) ; ICS /LABA combination product except SERETIDE approve FSC 500/50 generic product SYMBICORT approve dos frequency COPD ( 30 day ) ; SERETIDE , approve FSC 500/50 generic product , SYMBICORT approve dos frequency COPD ( 12 hour prior screen ) ; Phosphodiesterase 4 ( PDE4 ) Inhibitor ( roflumilast ) ( 14 day ) ; Longacting muscarinic antagonist ( tiotropium , aclidinium , glycopyrronium , UMEC ) ( 7 day ) ; Inhaled long act beta2 agonist ( LABA ) ( salmeterol , formoterol : 48 hr ) olodaterol , indacaterol ( 14 day ) ; LAMA/LABA combination product ( Apply whichever mono component long washout ) Theophyllines ( 48 hour ) ; Oral beta2agonists ( Longacting : 48 hour ) ( Shortacting : 12 hour ) ; Inhaled short act beta2agonists ( 4 hour ) ; Inhaled shortacting anticholinergic ( 4 hour ) ; Inhaled shortacting anticholinergic/shortacting beta2agonist combination product ( 4 hour ) ; Any investigational medication ( 30 day within 5 drug halflives , whichever long ) . Note : Use study provide albuterol/salbutamol permit study , except 4hour period prior spirometry test . Intraarticular epidural corticosteroid injection permit . Corticosteroids short term treatment COPD exacerbation allow Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , &lt; =12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , albuterol/salbutamol ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 , enter acute phase pulmonary rehabilitation program study . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Inability read : In opinion investigator , subject unable read and/or would able complete questionnaire . DISKUS trade mark GlaxoSmithKline Group Companies . Other company product name mention herein may property respective owner .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FEV1</keyword>
	<keyword>DPI</keyword>
	<keyword>ICS/LABA</keyword>
	<keyword>UMEC</keyword>
	<keyword>COPD</keyword>
</DOC>